APREA THERAPEUTICS INC (APRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.79-1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · APRE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Accelerate enrollment and dose escalation in ACESOT-1051 trial for APR-1051, targeting biomarker-defined cancers with planned clinical data updates.
Stated as a priority in 2 of last 2 quarters. Management emphasized accelerating enrollment and dose escalation in the ACESOT-1051 trial for APR-1051, with clinical data updates expected in Q4 2026. Cash increased from $14.6M at 2025-Q4 to $41.2M at 2026-Q2, supporting trial expansion. Operating loss rose slightly from $3.4M in 2026-Q1 to $4.0M in 2026-Q2, reflecting increased R&D spend. The trajectory shows delivering progress consistent with stated clinical development goals.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances.”
“Two partial responses observed in the ACESOT-1051 trial evaluating APR-1051; dose escalation ongoing with enrollment underway in the 300 mg cohort.”
Raise capital to extend cash runway and support clinical development, including a $30 million private placement closed in Q1 2026.
Stated as a priority in 2 of last 2 quarters. The company closed a $30 million private placement in Q1 2026, increasing cash from $14.6M at 2025-Q4 to $46.5M at 2026-Q1 and $41.2M at 2026-Q2. Management expects this to extend the cash runway into Q1 2028. The financial position has strengthened materially, delivering on the capital raise priority.
“Supported by the $30 million private placement that closed in Q1 2026, cash and cash equivalents were $41.2 million as of June 30, 2026.”
“Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051.”
Consider further development of ATRN-119 in combination with other anti-cancer therapies after pausing monotherapy trial ABOYA-119.
Stated as a priority in 2 of last 2 quarters. Management has paused ATRN-119 monotherapy trial and is exploring combination therapies with radiation, immuno-oncology agents, and ADCs. No revenue or clinical milestone data yet, so progress is limited but the strategic direction is consistent.
“ATRN-119 development in combination approaches could expand its therapeutic potential; discussions ongoing with academic centers.”
“ATRN-119 monotherapy trial paused; exploring combinations with radiation, immuno-oncology therapies, ADCs.”
Finish dose escalation and backfill expansion in ACESOT-1051 trial to characterize APR-1051 clinical activity by mid-2027.
Stated as a priority in 2 of last 2 quarters. Management expects to complete dose escalation and expansion in ACESOT-1051 by Q2 2027. Enrollment is accelerating but no clinical completion yet; trajectory is on track but pending future milestones.
“Completion of dose escalation and backfill expansion is anticipated in the second quarter of 2027.”
“Completion of dose escalation is anticipated in the second quarter of 2027.”
Provide updated clinical data from ACESOT-1051 trial at a medical meeting in the fourth quarter of 2026.
Stated as a priority in 2 of last 2 quarters. Management plans to report updated clinical data from ACESOT-1051 in Q4 2026. Enrollment is accelerating to support this update. The trajectory is consistent with management's stated timeline for clinical data disclosure.
“Aprea expects to report the next clinical data update from ACESOT-1051 at a medical meeting in the fourth quarter of 2026.”
“Further clinical updates from ACESOT-1051 are expected during Q2 2026; next update at ASCO 2026 in May.”
Over the trailing year it converted 1.04x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.